Hanall Biopharma Co., Ltd. (KRX:009420)

Market Cap	2.10T +52.2%
Revenue (ttm)	155.18B +11.7%
Net Income	-5.56B
EPS	-109.48
Shares Out	50.78M
PE Ratio	n/a
Forward PE	461.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	310,416
Average Volume	358,592
Open	40,800
Previous Close	41,450
Day's Range	38,750 - 42,300
52-Week Range	24,000 - 66,600
Beta	0.65
RSI	35.95
Earnings Date	Aug 14, 2026

About Hanall Biopharma

Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunct...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 009420

Financial Performance

In 2025, Hanall Biopharma's revenue was 155.18 billion, an increase of 11.69% compared to the previous year's 138.94 billion. Losses were -5.56 billion, 208.0% more than in 2024.